FrancophonIA/ELRC3.0 huggingface dataset:
English: ► After each injection, be sure to remove and discard the needle and store Mixtard without the needle attached.
Danish: ► Husk at fjerne og kassere nålen efter hver injektion, og opbevar Mixtard uden nålen påsat.
English: Needles and Mixtard Penfill must not be shared.
Danish: Nåle og Mixtard Penfill må ikke deles med andre.
English: Mixtard is human insulin with both a fast-acting and a long-acting effect.
Danish: Mixtard er en blanding af hurtigtvirkende og langtidsvirkende humant insulin.
English: ► Mixtard FlexPen is only suitable for injecting under the skin.
Danish: ► Mixtard FlexPen er kun egnet til indsprøjtning under huden.
English: ► Mixtard InnoLet is only suitable for injecting under the skin.
Danish: ► Mixtard InnoLet er kun egnet til indsprøjtning under huden.
English: Mixtard FlexPen is only suitable for injecting under the skin.
Danish: Mixtard FlexPen er kun egnet til indsprøjtning under huden.
English: Mixtard InnoLet is only suitable for injecting under the skin.
Danish: Mixtard InnoLet er kun egnet til indsprøjtning under huden.
English: Mixtard Penfill is only suitable for injecting under the skin using a reusable pen.
Danish: Mixtard Penfill er kun egnet til indsprøjtning under huden ved hjælp af en genanvendelig pen.
English: How to handle Mixtard 30 InnoLet
Danish: Sådan bruger du Mixtard 30 InnoLet
English: EU/1/02/231/033 1 pen of 3 ml EU/1/02/231/034 5 pens of 3 ml EU/1/02/231/035 10 pens of 3 ml
Danish: EU/1/02/231/033 1 pen a 3 ml EU/1/02/231/034 5 penne a 3 ml EU/1/02/231/035 10 penne a 3 ml
English: What Mixtard is and what it is used for What you need to know before you use Mixtard How to use Mixtard
Danish: Det skal du vide, før du begynder at tage Mixtard Sådan skal du tage Mixtard Bivirkninger
English: Each prefilled pen contains 300 IU of human insulin in 3 ml suspension for injection.
Danish: Hver fyldt pen indeholder 300 IE humant insulin i 3 ml injektionsvæske, suspension.
English: Mixtard FlexPen is only suitable for subcutaneous injections.
Danish: Mixtard 30 FlexPen er kun egnet til subkutan injektion.
English: ► Needles and Mixtard Penfill must not be shared.
Danish: ► Nåle og Mixtard Penfill må ikke deles med andre.
English: Mixtard InnoLet is only suitable for subcutaneous injections.
Danish: Mixtard 30 InnoLet er kun egnet til subkutan injektion.
English: Mixtard is a dual-acting insulin.
Danish: Mixtard er et blandingsinsulin.
English: EU/1/02/231/030 1 pen of 3 ml EU/1/02/231/031 5 pens of 3 ml EU/1/02/231/032 10 pens of 3 ml
Danish: EU/1/02/231/030 1 pen a 3 ml EU/1/02/231/031 5 penne a 3 ml EU/1/02/231/032 10 penne a 3 ml
English: Mixtard 30 FlexPen 100 international units/ml suspension for injection in pre-filled pen.
Danish: Mixtard 30 FlexPen 100 internationale enheder/ml injektionsvæske, suspension i fyldt pen.
English: ► Needles and Mixtard InnoLet must not be shared.
Danish: ► Nåle og Mixtard InnoLet må ikke deles med andre.
English: How to handle Mixtard 30 FlexPen
Danish: Sådan bruger du Mixtard 30 FlexPen
English: Mixtard 30 InnoLet 100 international units/ml suspension for injection in pre-filled pen.
Danish: Mixtard 30 InnoLet 100 internationale enheder/ml injektionsvæske, suspension i fyldt pen.
English: Mixtard 50 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 50 is essentially ‘sodiumfree'.
Danish: Mixtard 50 indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs. Mixtard 50 er stort set natriumfrit.
English: Mixtard 30 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 30 is essentially ‘sodiumfree'.
Danish: Mixtard 30 indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs. Mixtard 30 er stort set natriumfrit.
English: EU/1/02/231/003 1 vial of 10 ml EU/1/02/231/004 5 vials of 10 ml
Danish: EU/1/02/231/003 1 hætteglas a 10 ml EU/1/02/231/004 5 hætteglas a 10 ml
English: Mixtard 30 40 IU/ml Suspension for injection Insulin human
Danish: Mixtard 30 40 IE/ml Injektionsvæske, suspension Humant insulin
English: EU/1/02/231/001 1 vial of 10 ml EU/1/02/231/002 5 vials of 10 ml
Danish: EU/1/02/231/001 1 hætteglas a 10 ml EU/1/02/231/002 5 hætteglas a 10 ml
English: Mixtard 40 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 40 is essentially ‘sodiumfree'.
Danish: Mixtard 40 indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs. Mixtard 40 er stort set natriumfrit.
English: Mixtard 30 40 international units/ml suspension for injection in vial.
Danish: Mixtard 30 40 internationale enheder/ml injektionsvæske, suspension i hætteglas.
English: Mixtard contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard is essentially ‘sodium-free'.
Danish: Mixtard indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs. Mixtard er stort set natriumfrit.
English: Mixtard 50 Penfill 100 international units/ml suspension for injection in cartridge.
Danish: Mixtard 50 Penfill 100 internationale enheder/ml injektionsvæske, suspension i cylinderampul.
English: EU/1/02/231/011 1 cartridge of 3 ml EU/1/02/231/012 5 cartridges of 3 ml EU/1/02/231/013 10 cartridges of 3 ml
Danish: EU/1/02/231/011 1 cylinderampul a 3 ml EU/1/02/231/012 5 cylinderampuller a 3 ml EU/1/02/231/013 10 cylinderampuller a 3 ml
English: Mixtard 30 100 international units/ml suspension for injection in vial.
Danish: Mixtard 30 100 internationale enheder/ml injektionsvæske, suspension i hætteglas.
English: EU/1/02/231/014 1 cartridge of 3 ml EU/1/02/231/015 5 cartridges of 3 ml EU/1/02/231/016 10 cartridges of 3 ml
Danish: EU/1/02/231/014 1 cylinderampul a 3 ml EU/1/02/231/015 5 cylinderampuller a 3 ml EU/1/02/231/016 10 cylinderampuller a 3 ml
English: Mixtard 30 FlexPen 100 IU/ml Suspension for injection in pre-filled pen Insulin human
Danish: Mixtard 30 FlexPen 100 IE/ml Injektionsvæske, suspension i fyldt pen Humant insulin
English: Package leaflet: Information for the user Mixtard 30 40 IU/ml (international units/ml) suspension for injection in vial human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 30 40 IE/ml (internationale enheder/ml) injektionsvæske, suspension i hætteglas humant insulin
English: Mixtard 40 Penfill 100 international units/ml suspension for injection in cartridge.
Danish: Mixtard 40 Penfill 100 internationale enheder/ml injektionsvæske, suspension i cylinderampul.
English: Mixtard 30 100 IU/ml Suspension for injection Insulin human
Danish: Mixtard 30 100 IE/ml Injektionsvæske, suspension Humant insulin
English: Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge.
Danish: Mixtard 30 Penfill 100 internationale enheder/ml injektionsvæske, suspension i cylinderampul.
English: EU/1/02/231/017 1 cartridge of 3 ml EU/1/02/231/018 5 cartridges of 3 ml EU/1/02/231/019 10 cartridges of 3 ml
Danish: EU/1/02/231/017 1 cylinderampul a 3 ml EU/1/02/231/018 5 cylinderampuller a 3 ml EU/1/02/231/019 10 cylinderampuller a 3 ml
English: Mixtard 30 40 IU/ml Suspension for injection Insulin human SC
Danish: Mixtard 30 40 IE/ml Injektionsvæske, suspension Humant insulin s.c.
English: Mixtard 30 InnoLet 100 IU/ml Suspension for injection in pre-filled pen Insulin human
Danish: Mixtard 30 InnoLet 100 IE/ml Injektionsvæske, suspension i fyldt pen Humant insulin
English: Package leaflet: Information for the user Mixtard 30 FlexPen 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 30 FlexPen 100 IE/ml (internationale enheder/ml) injektionsvæske, suspension i fyldt pen humant insulin
English: Package leaflet: Information for the user Mixtard 50 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 50 Penfill 100 IE/ml (internationale enheder/ml) injektionsvæske, suspension i cylinderampul humant insulin
English: Mixtard 30 100 IU/ml Suspension for injection Insulin human SC
Danish: Mixtard 30 100 IE/ml Injektionsvæske, suspension Humant insulin s.c.
English: Package leaflet: Information for the user Mixtard 40 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 40 Penfill 100 IE/ml (internationale enheder/ml) injektionsvæske, suspension i cylinderampul humant insulin
English: Mixtard 30 Penfill 100 IU/ml Suspension for injection Insulin human
Danish: Mixtard 30 Penfill 100 IE/ml Injektionsvæske, suspension i cylinderampul Humant insulin
English: Package leaflet: Information for the user Mixtard 30 100 IU/ml (international units/ml) suspension for injection in vial human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 30 100 IE/ml (internationale enheder/ml) injektionsvæske, suspension i hætteglas humant insulin
English: Package leaflet: Information for the user Mixtard 30 InnoLet 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 30 InnoLet 100 IE/ml (internationale enheder/ml) injektionsvæske, suspension i fyldt pen humant insulin
English: Package leaflet: Information for the user Mixtard 30 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Danish: Indlægsseddel: Information til brugeren Mixtard 30 Penfill 100 IE/ml (internationale enheder/ml) injektionsvæske, suspension i cylinderampul humant insulin
English: Mixtard 50 Penfill 100 IU/ml Suspension for injection Insulin human
Danish: Mixtard 50 Penfill 100 IE/ml Injektionsvæske, suspension i cylinderampul Humant insulin
English: Mixtard 40 Penfill 100 IU/ml Suspension for injection Insulin human
Danish: Mixtard 40 Penfill 100 IE/ml Injektionsvæske, suspension i cylinderampul Humant insulin
English: Mixtard 30 FlexPen 100 IU/ml Suspension for injection Insulin human
Danish: Mixtard 30 FlexPen 100 IE/ml Injektionsvæske, suspension Humant insulin s.c.
English: Mixtard 30 InnoLet 100 IU/ml Suspension for injection Insulin human
Danish: Mixtard 30 InnoLet 100 IE/ml Injektionsvæske, suspension Humant insulin s.c.
English: Do not use this medicine after the expiry date, which is stated on the vial label and carton after ‘EXP'.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og hætteglasset efter ‘EXP'.
English: Making the injection
Danish: Påsætning af nålen
English: Mixtard 30 InnoLet EU/1/02/231/030 EU/1/02/231/031 EU/1/02/231/032
Danish: Mixtard 30 InnoLet EU/1/02/231/030
English: Ebixa should be given once a day at the same time every day.
Danish: Ebixa skal gives en gang dagligt på samme tidspunkt hver dag.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ebixa on 15 May 2002.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Ebixa den 15. maj 2002.
English: The full EPAR for Ebixa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Ebixa findes på agenturets websted: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Ebixa.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Ebixa.
English: To prevent side effects, the dose of Ebixa is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Danish: For at undgå bivirkninger øges dosis af Ebixa gradvist i løbet af de tre første uger af behandlingen: I den første uge er dosis 5 mg, i den anden uge er den 10 mg, og i den tredje uge er den 15 mg. Fra uge fire og fremover er den anbefalede vedligeholdelsesdosis 20 mg én gang dagligt.
English: Other information about Ebixa
Danish: Andre oplysninger om Ebixa
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ebixa.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Ebixa.
English: Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another.
Danish: Signalstoffer er kemiske stoffer i nervesystemet, der gør det muligt for nerveceller at meddele sig til hinanden.
English: The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Ebixa should be reassessed on a regular basis.
Danish: Tolerance og dosis bør vurderes inden for 3 måneder efter behandlingens start, og herefter bør fordelene ved at fortsætte behandlingen med Ebixa regelmæssigt genvurderes.
English: For more information about treatment with Ebixa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Ebixa, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: Ebixa was compared with placebo (a dummy treatment) over 24 to 28 weeks.
Danish: Ebixa blev sammenlignet med placebo (en virkningsløs behandling) i en periode på 24 til 28 uger.
English: The CHMP decided that Ebixa's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: CHMP besluttede, at fordelene ved Ebixa opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
English: Ebixa was more effective than placebo at controlling the symptoms of Alzheimer's disease.
Danish: Ebixa var mere effektivt end placebo til at begrænse symptomerne på Alzheimers sygdom.
English: However, when these results were considered along with those of the three additional studies, it was noted that the effect of Ebixa was smaller in patients with mild disease.
Danish: Men når disse resultater blev sammenholdt med resultaterne af de tre supplerende undersøgelser, fremgik det, at virkningen af Ebixa var mindre hos patienter med lettere sygdom.
English: The most common side effects with Ebixa (seen in between 1 and 10 patients in 100) are somnolence (sleepiness), dizziness, hypertension (high blood pressure), dyspnoea (difficulty breathing), constipation, headache and drug hypersensitivity (allergy to the medicine).
Danish: De hyppigste bivirkninger ved Ebixa (som optræder hos mellem 1 og 10 patienter ud af 100) er somnolens (søvnighed), svimmelhed, for højt blodtryk, dyspnø (vejrtrækningsbesvær), forstoppelse og hovedpine og lægemiddeloverfølsomhed (allergi over for lægemidlet).
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Ebixa by the patient.
Danish: Behandling bør kun iværksættes, hvis patienten har en omsorgsgiver, der regelmæssigt overvåger patientens indtagelse af Ebixa.
English: Ebixa has been studied in three main studies including a total of 1,125 patients with Alzheimer's disease, some of whom had taken other medicines for their disease in the past.
Danish: Ebixa blev anvendt i tre hovedundersøgelser med i alt 1 125 patienter med Alzheimers sygdom, hvoraf nogle tidligere havde fået anden medicin mod sygdommen.
English: Ebixa is also available as an oral solution, which is supplied with a pump that delivers 5 mg memantine hydrochloride with each activation.
Danish: Ebixa fås også som oral opløsning, der fås med en pumpe, som afgiver 5 mg memantinhydrochlorid ved hver aktivering.
English: Ebixa should not be used in people who may be hypersensitive (allergic) to memantine hydrochloride or any of the other ingredients.
Danish: Ebixa bør ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for memantinhydrochlorid eller andre af indholdsstofferne.
English: The active substance in Ebixa, memantine hydrochloride, is an antidementia medicine.
Danish: Det aktive stof i Ebixa, memantinhydrochlorid, er et middel mod demens.
English: What is the risk associated with Ebixa?
Danish: Hvilken risiko er der forbundet med Ebixa?
English: Ebixa is used to treat patients with moderate to severe Alzheimer's disease.
Danish: Ebixa anvendes til behandling af moderat til svær Alzheimers sygdom.
English: Ebixa was also studied in three additional studies including a total of 1,186 patients with mild to severe disease.
Danish: Ebixa blev desuden anvendt i tre supplerende undersøgelser med tilsammen 1 186 patienter med let til svær sygdom.
English: Ebixa is a medicine that contains the active substance memantine hydrochloride.
Danish: Ebixa er et lægemiddel, der indeholder det aktive stof memantinhydrochlorid.
English: In the study of moderately severe to severe disease, patients taking Ebixa had fewer symptoms than those taking placebo after 28 weeks, as measured on both global and functional scores.
Danish: I undersøgelsen af patienter med moderat svær til svær sygdom resulterede Ebixa efter 28 uger i færre symptomer end placebo, målt både på samlet score og funktionsscore.
English: Why has Ebixa been approved?
Danish: Hvorfor blev Ebixa godkendt?
English: For the full list of all side effects reported with Ebixa, see the package leaflet.
Danish: Den fuldstændige liste over alle de indberettede bivirkninger ved Ebixa fremgår af indlægssedlen.
English: What is Ebixa?
Danish: Hvad er Ebixa?
English: In the two studies of mild to moderate disease, patients on Ebixa had less severe symptoms after 24 weeks, as measured on the global and cognitive scores.
Danish: I de to undersøgelser af let til moderat sygdom havde de patienter, der fik Ebixa, efter 24 uger færre alvorlige symptomer.
English: How has Ebixa been studied?
Danish: Hvordan blev Ebixa undersøgt?
English: What is Ebixa used for?
Danish: Hvad anvendes Ebixa til?
English: What benefit has Ebixa shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Ebixa?
English: How is Ebixa used?
Danish: Hvordan anvendes Ebixa?
English: How does Ebixa work?
Danish: Hvordan virker Ebixa?
English: This summary was last updated in 02-2017.
Danish: Dette sammendrag blev sidst ajourført i 02-2017.
English: Doses are adjusted as necessary.
Danish: Doserne tilpasses efter behov.
English: On average, patients in the study were followed up for 3.1 years.
Danish: Patienterne blev i gennemsnit fulgt i 3,1 år.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Synjardy on 27 May 2015.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Synjardy den 27. maj 2015.
English: This is a summary of the European public assessment report (EPAR) for Synjardy.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Synjardy.
English: Synjardy must not be used in patients with:
Danish: Synjardy må ikke anvendes hos patienter med:
English: The full EPAR and risk management plan summary for Synjardy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR og resuméet af risikostyringsplanen for Synjardy findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Empagliflozin has been authorised in the EU under the trade name Jardiance since 2014.
Danish: Empagliflozin har været godkendt i EU under handelsnavnet Jardiance siden 2014.
English: Other information about Synjardy
Danish: Andre oplysninger om Synjardy
English: • in patients who are already taking metformin and empagliflozin as separate tablets.
Danish: • hos patienter, der i forvejen tager metformin og empagliflozin som separate tabletter.
English: What is Synjardy and what is it used for?
Danish: Hvad er Synjardy, og hvad anvendes det til?
English: What measures are being taken to ensure the safe and effective use of Synjardy?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Synjardy?
English: It is not intended to provide practical advice on how to use Synjardy.
Danish: Det er ikke en praktisk vejledning i, hvordan Synjardy bør anvendes.
English: Supportive evidence was provided from several further studies.
Danish: Dette blev underbygget af flere andre undersøgelser.
English: Synjardy is used:
Danish: Synjardy anvendes:
English: This leads to a high level of glucose in the blood.
Danish: Dette fører til et højt glukoseindhold i blodet.
English: • liver impairment, or problems with alcoholism or alcohol intoxication.
Danish: • nedsat leverfunktion eller problemer med alkoholisme eller alkoholforgiftning.
English: Why is Synjardy approved?
Danish: Hvorfor blev Synjardy godkendt?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy's benefits are greater than its risks and recommended that it be approved for use in the EU.
Danish: Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Synjardy opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: Among these, in patients who were also taking metformin (the other active substance in Synjardy), the three major cardiovascular events occurred in 9.9% (344 out of 3,459) of patients receiving empagliflozin and in 10.9% (189 out of 1,734) of patients receiving placebo.
Danish: Blandt disse, hos patienter, der også tog metformin (det andet aktive stof i Synjardy), indtraf de tre væsentligste hjerte-kar-hændelser hos 9,9 % (344 ud af 3 459) af de patienter, der modtog empagliflozin, og hos 10,9 % (189 ud af 1 734) af de patienter, der modtog placebo.
English: Synjardy is a diabetes medicine used with diet and exercise to treat adults with type 2 diabetes.
Danish: Synjardy er et lægemiddel mod diabetes, der anvendes sammen med diæt og motion til at behandle voksne med type 2-diabetes.
English: The main measure of effectiveness was the reduction in the level of a substance in the blood called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment.
Danish: Det primære effektmål var reduktionen af mængden af et stof i blodet kaldet glykosyleret hæmoglobin (HbA1c) efter 24 ugers behandling.
English: Because of concerns about the balance of benefit and risk in patients with reduced kidney function taking the fixed-dose combination, the CHMP recommended restricting its use in these patients.
Danish: På grund af betænkeligheder ved forholdet mellem fordele og risici hos patienter med nedsat nyrefunktion, der tog fastdosiskombinationen, anbefalede CHMP begrænsning af anvendelsen heraf hos sådanne patienter.
English: Similar benefits were seen in the studies regardless of the other diabetes medicines being taken.
Danish: Undersøgelserne viste tilsvarende fordele, uanset hvilke andre lægemidler mod sukkersyge, der blev anvendt.
English: What are the risks associated with Synjardy?
Danish: Hvilke risici er der forbundet med Synjardy?
English: • metabolic acidosis (when the body produces more acid than it gets rid of) or diabetic pre-coma (dangerous complications of diabetes);
Danish: • metabolisk acidose (når kroppen producerer mere syre, end den udskiller) eller diabetisk prækoma (farlige komplikationer ved sukkersyge)
English: The recommended dose of Synjardy is one tablet twice a day with meals, and treatment is normally started with a tablet that supplies the dose of metformin the patient is already taking, together with the lowest dose (5 mg) of empagliflozin.
Danish: Den anbefalede dosis Synjardy er én tablet to gange dagligt i forbindelse med et måltid, og behandlingen påbegyndes normalt med én tablet som supplement til den dosis metformin, patienten allerede får, sammen med den laveste dosis (5 mg) empagliflozin.